News | Women's Health | December 07, 2015

iCAD Featured New Technology for Automated Breast Density Assessment and Showcased Solutions for Tomosynthesis at RSNA 2015

iCAD demonstrated iReveal breast density assessment for 2-D and tomosynthesis mammography, PowerLook Advanced Mammography Platform and VeraLook colon polyp detection technology

iCAD Featured New Technology for Automated Breast Density Assessment and Showcased Solutions for Tomosynthesis at RSNA 2015

December 7, 2015 — iCAD, Inc. featured its latest solutions for advanced image analysis and workflow tools for the early identification of cancer at the Radiological Society of North American (RSNA) 2015 Annual Meeting in Chicago. The company showcased recent product advances including iReveal, an automated breast density assessment solution, PowerLook Advanced Mammography Platform, featuring the company’s flagship advanced cancer detection product, VeraLook colon polyp detection technology and new tomosynthesis solutions, shown as works in progress.  

The iReveal automated breast density solution is designed to standardize the assessment and reporting of breast density. iReveal assists radiologists in evaluating and scoring breast density to identify patients who may be at higher risk of developing breast cancer. With an appearance-based approach, iReveal uses an innovative technique that analyzes the structure, texture, and dispersion of the fibroglandular tissue in the breast, then calibrates the results to a density category corresponding to the BI-RADS breast density reporting system. iCAD will also be previewing a breast density assessment solution for tomosynthesis.

“The issue of breast density is rapidly emerging as a pivotal factor in the diagnosis of breast cancer, and iReveal is another great example of our continued focus to detect cancer earlier, when it may be more easily treated,” said Ken Ferry, CEO of iCAD. “Currently, 24 states have adopted legislation that require patients to be notified of their breast density.  As these laws expand to other states and perhaps nationally, it is essential for radiologists to have access to superior technology that delivers rapid, automatic, and reproducible breast density assessment results.”

The PowerLook AMP solution delivers superior performance for accurate detection of breast cancer.  VeraLook automatically detects polyps in computed tomography colonography (CTC) images assisting in the interpretation of CTC exams. As a work in progress, iCAD also be demonstratied tomosynthesis workflow tools to support cancer detection and increased reading efficiency.

“This has been an exciting year at iCAD where our focus on innovation and product development have delivered some important advances that will significantly improve cancer diagnosis and treatment in the years ahead,” Ferry added.

For more information: www.icadmed.com

Related Content

Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
The MOZART Supra Specimen Tomosynthesis System is the latest generation of 3-D imaging for breast cancer surgery.
News | Breast Imaging | November 08, 2018
KUBTEC announced the launch of a new innovation in the treatment of breast cancer. The Mozart Supra Specimen...
Feature | Breast Imaging | November 07, 2018 | By Jeff Zagoudis
Breast imaging technology has experienced major growth over the last decade or so, and a new report suggests the mark
Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing  information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Philips’ Compressed SENSE technology helps shorten MRI exams by eliminating redundant radiofrequency signals from the acquisition phase. The software reconstructs any missing information to maintain high image quality. (Images courtesy of Philips/University Hospital Cologne)

Feature | Breast Imaging | November 05, 2018 | By Jeff Zagoudis
The incidence of breast cancer is rising globally, with an estimated 1 in 8 women diagnosed in their lifetime and 40,...
Deaconess Health System Chooses Sectra as Enterprise Imaging Vendor
News | Enterprise Imaging | November 02, 2018
International medical imaging information technology (IT) and cybersecurity company Sectra will install its enterprise...
Volpara Enterprise Cloud Reaches 1 Million Mammograms Stored
News | Mammography | October 31, 2018
Volpara Solutions announced that the data stored in the Volpara Enterprise cloud now exceeds 1 million mammographic...
Etta Pisano Named American College of Radiology Chief Research Officer
News | Radiology Business | October 25, 2018
October 25, 2018 — Breast imaging research pioneer Etta Pisano, M.D., FACR, has been named...
DenseBreast-info.org Launches Patient Education Video Series
News | Breast Density | October 24, 2018
DenseBreast-info.org (DB-I) announced the release of "Let's Talk About Dense Breasts," a series of three informational...
Fewer, larger individual doses of radiation lead to similar adverse effects to normal tissue after 10 years as with conventional radiation therapy for early breast cancer
News | ASTRO | October 22, 2018
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer,
DCIS, ductal carcinoma in situ, radiation therapy, survival benefit, Brigham and Women's Hospital study. #ASTRO2018 #ASTRO #ASTRO18

Image courtesy of Barco

News | ASTRO | October 21, 2018
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservatio